- Protocol Short Name and Number: Acute GVHD, 0302
- Protocol Long Name: Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids
- Protocol (PDF)
- Consent Forms
- Frequently Asked Questions
- Key Personnel
- BMT CTN # 0302 Protocol Chair: Dan Weisdorf, MD
- BMT CTN # 0302 Protocol Officer: Marcelo Pasquini, MD
- BMT CTN # 0302 Medical Monitor: Mary Eapen, MD
- BMT CTN # 0302 Protocol Coordinator: bmtctn@emmes.com
- Keywords: Etanercept, Mycophenolate Mofetil, MMF, Denileukin Diftitox (Ontak), Pentostatin, Treatment, Pediatric, Graft versus Host Disease, GVHD, Graft vs. Host Disease, Child, Children, Teen, Adolescent
The BMT CTN #0302 study met its target accrual of 180 patients and closed enrollment on March 24, 2008.